{"id":"abt-652","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, which suppresses the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce inflammation in conditions driven by excessive immune activation, particularly in respiratory and inflammatory diseases.","oneSentence":"ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:31.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT01579279","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain","status":"TERMINATED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-04","conditions":"Diabetic Neuropathic Pain","enrollment":1},{"nctId":"NCT01444365","phase":"PHASE2","title":"A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Osteoarthritis of the Knee","enrollment":202},{"nctId":"NCT01207115","phase":"PHASE2","title":"A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Osteoarthritis of the Knee","enrollment":322},{"nctId":"NCT01124851","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness","status":"COMPLETED","sponsor":"Abbott","startDate":"2010-08","conditions":"Sleep Disorder","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABT-652","genericName":"ABT-652","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD), Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}